These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6228294)

  • 21. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
    Malmström H; Rasmussen S; Simonsen E
    Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
    Kurbacher CM; Bruckner HW; Cree IA; Kurbacher JA; Wilhelm L; Pöch G; Indefrei D; Mallmann P; Andreotti PE
    Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary phase I clinical study and pharmacokinetics of (1,2-diaminocyclohexane) (isocitrato) platinum (II) or PHIC.
    Gouyette A; Ducret JP; Caillé P; Amiel JL; Rouëssé J; Foka M; Carde P; Hayat M; Sancho-Garnier H
    Anticancer Res; 1986; 6(5):1127-32. PubMed ID: 3800320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
    Markman M; Reichman B; Hakes T; Rubin S; Lewis JL; Jones W; Barakat R; Curtin J; Almadrones L; Hoskins W
    Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens.
    Muggia FM; Groshen S; Russell C; Jeffers S; Chen SC; Schlaerth J; Curtin J; Morrow CP
    Gynecol Oncol; 1993 Aug; 50(2):232-8. PubMed ID: 8375739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
    Tarraza HM; Boyce CR; Smith WG; Jones MA
    Gynecol Oncol; 1993 Sep; 50(3):287-90. PubMed ID: 8406188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
    Egorin MJ; Van Echo DA; Tipping SJ; Olman EA; Whitacre MY; Thompson BW; Aisner J
    Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
    Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
    Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
    Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The value of a Tenckhoff catheter in ovarian cancer].
    Kato N; Arakawa A; Yasui Y; Suzumori K; Suzumori K; Yagami Y
    Gan To Kagaku Ryoho; 1991 May; 18(6):1025-30. PubMed ID: 2029187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
    Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
    Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route.
    Casper ES; Kelsen DP; Alcock NW; Lewis JL
    Cancer Treat Rep; 1983 Mar; 67(3):235-8. PubMed ID: 6682012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Significance and effects of intraperitoneal cisplatin administration for ovarian cancer].
    Shimizu A; Ookubo K; Hasegawa J; Endoh T; Fujiwara O; Yoda A; Okuyama D; Narabayashi A; Kimura T; Takahashi J; Notake Y
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1801-5. PubMed ID: 10560398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis.
    Gouyette A; Lemoine R; Adhemar JP; Kleinknecht D; Man NK; Droz JP; Macquet JP
    Cancer Treat Rep; 1981; 65(7-8):665-8. PubMed ID: 7195773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.